TRINETRA › Sectors › Healthcare
Advanced Enzyme Technologies Limited (ADVENZYMES) — share price, P/E and fundamentals
Advanced Enzyme Technologies Limited (NSE: ADVENZYMES) closed at ₹260.00 on 30 Oct 2026, -17.0% over one year, against a 52-week range of ₹246.80 – ₹419.00.
In the quarter ended 30 Sept 2026 (consolidated, filed 31 Oct 2026) it reported revenue of ₹215 cr and net profit of ₹48 cr, a 22.5% net margin; revenue grew 16.2% and profit grew 15.5% year on year.
On four consecutive filed quarters its trailing P/E is 16.8; since 13 May 2025 its own P/E has ranged from 16.9 to 30.7 (median 24.8), and today's reading is higher than 1% of those 363 trading days.
From the balance sheet dated 30 Sept 2026: return on equity 11.6%, ROCE 15.6%, debt-to-equity 0.01, Piotroski F-score 5 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 81% of 63 sector peers; PBT margin higher than 87% of 63 sector peers; ROE higher than 35% of 63 sector peers.
Key figures
| Last close | ₹260.00 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -11.2% / -13.1% / -17.0% |
| 52-week low – high | ₹246.80 – ₹419.00 |
| Market capitalisation | ₹2,867 cr |
| Trailing P/E | 16.8 |
| Price / book | 1.72 |
| EV / EBITDA | 9.6 |
| Earnings yield | 6.0% |
| TTM EPS | ₹15.50 |
| TTM net profit | ₹171 cr |
| Quarter revenue | ₹215 cr |
| Quarter net profit | ₹48 cr |
| Net margin | 22.5% |
| Revenue growth (YoY) | +16.2% |
| Profit growth (YoY) | +15.5% |
| Return on equity | 11.6% |
| ROCE | 15.6% |
| Debt / equity | 0.01 |
| Current ratio | 8.91 |
| Free cash flow | ₹26 cr |
| Piotroski F-score | 5 / 9 |
| Average daily turnover (50 days) | ₹5.8 cr |
Against Healthcare peers
| Metric | ADVENZYMES | Peer median | Percentile |
|---|---|---|---|
| Net margin | 22.52 | 12.67 | 81 |
| PBT margin | 32.05 | 17.57 | 87 |
| ROE | 11.61 | 13.87 | 35 |
| ROCE | 15.64 | 17.26 | 40 |
| Debt / equity | 0.01 | 0.11 | 28 |
| FCF margin | 6.30 | -0.87 | 60 |
| Cash conversion | 0.86 | 1.25 | 23 |
| Trailing P/E | 16.78 | 43.26 | 7 |
Questions
What is the P/E ratio of Advanced Enzyme Technologies Limited?
Advanced Enzyme Technologies Limited's trailing P/E is 16.8, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026. Since 13 May 2025 its P/E has ranged 16.9–30.7.
What were Advanced Enzyme Technologies Limited's latest quarterly results?
For the quarter ended 30 Sept 2026, Advanced Enzyme Technologies Limited reported revenue of ₹215 cr and net profit of ₹48 cr (consolidated), filed with the exchange on 31 Oct 2026.
What is Advanced Enzyme Technologies Limited's ROE?
Return on equity is 11.6% based on the balance sheet dated 30 Sept 2026.
Does Advanced Enzyme Technologies Limited have debt?
Debt-to-equity is 0.01 on the balance sheet dated 30 Sept 2026.
What is ADVENZYMES's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, ADVENZYMES traded between ₹246.80 and ₹419.00.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Apollo Hospitals Enterprise Limited (APOLLOHOSP)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Sept 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.